Edgewise Therapeutics, Inc.
EWTXNext catalyst
Sevasemten Dose 2
Duchenne Muscular Dystrophy
Get an email about EWTX's next catalysts
Track Edgewise Therapeutics (EWTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 2 past
Sevasemten Dose 2 Phase 2 Est. Readout
Estimated primary completion for Sevasemten Dose 2 trial (NCT05540860) in Duchenne Muscular Dystrophy. Topline data typically follows completion by weeks to months.
SourceSevasemten Dose 2 Phase 2 Est. Readout
Primary completion for Sevasemten Dose 2 trial (NCT06100887) in Duchenne Muscular Dystrophy
SourceSevasemten Dose 1 Phase 2 Est. Readout (FOX)
Estimated primary completion for Sevasemten Dose 1 trial (NCT06100887) in Duchenne Muscular Dystrophy. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
EDG-7500
Hypertrophic Cardiomyopathy
Sevasemten
Becker Muscular Dystrophy
Sevasemten Dose 1
Duchenne Muscular Dystrophy
Sevasemten Dose 2
Duchenne Muscular Dystrophy
EDG-15400
Heart Failure With Preserved Ejection Fraction
Sevasemten Dose 4
Duchenne Muscular Dystrophy
Sevasemten Dose 5
Duchenne Muscular Dystrophy
Sevasemten Dose 3
Duchenne Muscular Dystrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EDG-7500 | Phase 2 | Hypertrophic Cardiomyopathy | - | - |
Sevasemten | Phase 2 | Becker Muscular Dystrophy | - | - |
Sevasemten Dose 1 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Sevasemten Dose 2 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
EDG-15400 | Phase 2 | Heart Failure With Preserved Ejection Fraction | - | - |
Sevasemten Dose 4 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Sevasemten Dose 5 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Sevasemten Dose 3 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Frequently asked questions
What is in Edgewise Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Edgewise Therapeutics, Inc.'s (EWTX) pipeline across Phase 2. Its lead program is Sevasemten Dose 2 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Edgewise Therapeutics, Inc.'s next FDA catalyst?→
Edgewise Therapeutics, Inc.'s (EWTX) next tracked catalyst is a Phase 2 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EWTX biotech catalysts?→
Add EWTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Edgewise Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.